“Taking the early commercial lead in the tough terrain of healthcare requires the tightest strategic footing and the collective wisdom of global expert-based perspectives. We provide a critical filter through which solid decisions and forecasts can be made. Our clients look to us for intellectual honesty and transparency to help manage uncertainty and risk. It’s the only way to ensure that priorities are aligned and that confident, supportable next steps can be taken.”
Prior to co-founding Aptis Partners, she was a Senior Vice President of Kendall Strategies (Feinstein Kean Healthcare), where she established, grew and managed the commercial research and strategy practice. Earlier in her career she held marketing roles for National Medical Care (Fresenius), where she developed, produced and marketed nutrition products for the company’s national program of medically supervised weight reduction programs for the morbidly obese. She also was the Marketing Director of a venture-backed company developing nutrition products for oncology patients. She began her career as a nutritionist and registered dietitian at Brigham and Women’s Hospital, where she established and directed the nutrition services in two of the Brigham’s community health centers.
“Making sense of the unknowns with an early-stage product or technology poses challenges that can only be properly addressed by the full involvement of a consultancy’s partners. Aptis was founded on that premise and the result is a business model that is significantly different from other consulting firms. At Aptis, Susan and I are fully involved in all aspects of every project not only because it is necessary but because we thrive on this type of work.”
Prior experience includes roles as Editor of IN VIVO: The Business and Medicine Report as well as a news reporter for MDDI Reports (“The Gray Sheet”). He has held business planning positions in the international pharmaceuticals division at Eli Lilly and Company, the domestic business planning group responsible for Eli Lilly’s diversification into the medical device and diagnostic industry, and with Therics, a start-up company developing a 3D printing process for making medical devices, tissue healing matrices and drug delivery systems. Tucker started his career as a bench chemist at Squibb Corporation.